Resverlogix Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Donald J. McCaffrey
- Full Time Employees
- 17
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 4820 Richard Road SW Calgary AB Canada T3E 6L1
- IPO Date
- Oct 12, 2001
- Website
- resverlogix.com
- Similar Companies
- Business
- Resverlogix Corp. is a Calgary, Alberta-based late-stage clinical biotechnology company founded in 2001 that develops epigenetic therapies to treat patients with chronic diseases by regulating disease-causing gene expression through inhibition of bromodomain and extra-terminal (BET) proteins. The company's lead product candidate is apabetalone (RVX-208), a selective BET inhibitor targeting the second bromodomain (BD2) for indications including high-risk cardiovascular disease in patients with type 2 diabetes mellitus and low high-density lipoprotein levels as evaluated in the global Phase 3 BETonMACE clinical trial, post-COVID-19 conditions, pulmonary arterial hypertension, end-stage renal disease, chronic kidney disease, neurodegenerative diseases, Fabry disease, peripheral artery disease, and other orphan indications such as facioscapulohumeral muscular dystrophy. It maintains a partnership with EVERSANA to support commercialization of apabetalone for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States; Shenzhen Hepalink Pharmaceutical Group Co., Ltd., its largest shareholder, holds a US$6.0 million secured debenture extended in May 2024 for two years to May 13, 2026, with conversion privileges eliminated and interest rate increased to 18% per annum. Recent developments include the appointment of Bradley Glass, General Counsel of Hepalink USA, Inc., to the board of directors in November 2025; shareholder approval of the board at the June 2025 annual meeting; a presentation on apabetalone's anti-inflammatory and anti-fibrotic effects in cardiac fibroblasts at the European Society of Cardiology Congress 2024; and ongoing advancements in Zenith Capital funding during 2025. Operations are primarily in Canada with a U.S. office in San Francisco, California, and the company trades on the Toronto Stock Exchange under the symbol RVX.TO.
Company News
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Resverlogix Announces One-Year Extension of Debenture
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
Resverlogix Corp. Announces Issuance of MCTO by ASC
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
Resverlogix Appoints Bradley Glass to Board of Directors
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
Resverlogix Announces Change to Its Board of Directors
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.